Please use this form to send any questions, bug reports, or suggestions. If you are reporting a bug, please include detailed information about what you were doing, and attach any relevant screenshots, if possible.
Thank you for providing your feedback! Someone will be in touch with you shortly. This window will automatically close in 5 seconds.
Dasatinib is an oral dual BCR/ABL and Src family tyrosine kinase inhibitor approved for use in patients with chronic myelogenous leukemia (CML). The main targets of Dasatinib, are BCRABL, SRC, Ephrins and GFR.
For the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia with resistance or intolerance to prior therapy. Also indicated for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy.
Dasatinib is an oral dual BCR/ABL and Src family tyrosine kinase inhibitor
Mechanism of action
Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ. Based on modeling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase. In vitro, dasatinib was active in leukemic cell lines representing variants of imatinib mesylate sensitive and resistant disease. Dasatinib inhibited the growth of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL. Under the conditions of the assays, dasatinib was able to overcome imatinib resistance resulting from BCR-ABL kinase domain mutations, activation of alternate signaling pathways involving the SRC family kinases (LYN, HCK), and multi-drug resistance gene overexpression.
Route of administration
Antineoplastic and Immunomodulating Agents
Chemical Actions and Uses
Combined Inhibitors of CYP3A4 and P-glycoprotein
Cytochrome P-450 CYP1A2 Substrates
Cytochrome P-450 CYP3A Inhibitors
Cytochrome P-450 CYP3A4 Inhibitors (weak)
Cytochrome P-450 CYP3A4 Substrates
Heterocyclic Compounds, 1-Ring
Molecular Mechanisms of Pharmacological Action
Protein Kinase Inhibitors
QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying)
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682